Sunvozertinib Tops Platinum Doublet in First-Line EGFR Exon 20 NSCLC

Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaSunvozertinib (Zegfrovy, Dizal) was superior to platinum-based chemotherapy in the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations, according to topline results from WU-KONG28 trial.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { m